Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Endometriosis, and Chemoresistance Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for AKR1C1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | AKR1C1 Wild-Type & Mutant Recombinant Proteins (e.g., rs139588200, rs760575583). High purity (>95%), Sequence Verified, Endotoxin <1 EU/µg, Theoretical MW confirmed. | View AKR1C1 Products |
| Gene Delivery | AKR1C1 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines in enzymatic, resistance, and PROTAC degradation assays. | View AKR1C1 Products |
| Benchmark Ab | Anti-AKR1C1 Recombinant Antibody. Research-grade positive control for ELISA, Western blot, and assay validation. | View AKR1C1 Products |
| Validator | AKR1C1 siRNA Set. For specific knockdown and phenotype rescue verification in cell-based assays. | View AKR1C1 Products |
| Related Target A | AKR1C2 (98% sequence identity). Essential subfamily counter-screening target for selectivity. | View AKR1C2 Products |
| Related Target B | AKR1C3 (86% identity). Shared steroid/prostaglandin pathway; defines inhibitor selectivity window. | View AKR1C3 Products |
| Related Target C | PGR (Progesterone Receptor). Primary downstream biological partner in endocrine signaling. | View PGR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform selectivity (vs AKR1C2, AKR1C3, AKR1C4) | Human AKR1C1/1C2/1C3/1C4 recombinant proteins as a panel; all >95% purity, sequence and mass spec verified. |
| Enzymatic activity & HTS readiness | N-terminally purified WT and cofactor-binding mutants; endotoxin <1 EU/µg for cell-free assays. |
| Drug resistance & mutant profiling | AKR1C1 mutant library (catalytic loop variants; dbSNP: rs139588200, rs760575583) for mechanistic resistance studies. |
| Intracellular localization & cellular stability | E. coli or HEK293 expressed soluble recombinant proteins with theoretical MW validation. |
| Lack of controls | Sequence-verified benchmark antibodies and validated siRNA included for specificity checks. |
Live AKR1C1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The AKR1C1 (20α-hydroxysteroid dehydrogenase) target remains anchored in preclinical oncology and endocrine drug discovery. While no dedicated AKR1C1 therapeutic has advanced beyond early-stage clinical trials, its documented role in progesterone inactivation and resistance to platinum-based and anthracycline chemotherapies has renewed commercial interest. Major pharmaceutical players are not yet prioritizing standalone AKR1C1 programs; instead, the target is being evaluated within broader AKR1C family inhibitor portfolios and chemo-sensitization strategies. As first-generation pan-AKR1C scaffolds progress, the next wave of R&D is targeting isoform-selective inhibition and AKR1C1-specific PROTAC degraders to minimize off-target hormonal disruption. Key indications include ovarian, endometrial, breast, prostate, and lung cancers, as well as endometriosis. The market is expected to see 2–3 combination therapies reach IND stage within 3–5 years, alongside the emergence of selective degraders.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Academic consortia, early-stage biotechs | Chemo-resistant solid tumors (ovarian, endometrial, lung, breast, prostate, leukemia) | Isoform selectivity panel (need purified AKR1C1/1C2/1C3/1C4 proteins) |
| PROTAC / Degrader | Emerging academic & biotech programs | Solid tumors, endometriosis | Cellular degradation assay (need Lentivirus ORF stable cell lines) |
| Chemosensitization Combination | Oncology pharma pipelines | Platinum- and anthracycline-resistant tumors | Resistance mutant profiling (need mutant recombinant proteins, e.g., rs139588200, rs760575583) |
Key Considerations for Drug Development
Selectivity: The Ultimate Challenge
AKR1C1 shares 98% sequence identity with AKR1C2 and 86% with AKR1C3. High selectivity (>100-fold IC50 window) is critical to avoid off-target steroid/prostaglandin metabolism disruption. TarMart provides a validated homolog panel (AKR1C1–1C4) for accurate counter-screening.
Mechanism of Action
Inhibitors may target the substrate pocket (competitive), NADPH cofactor pocket (uncompetitive), or allosteric sites. Cofactor pocket binders often offer better isoform selectivity but require high cell permeability and sustained activity in high intracellular NADPH.
Resistance Mutant Profiling
Acquired mutations in the catalytic triad or surrounding loops (e.g., residues 120–130, 270–280) can reduce drug affinity. The known dbSNP variants rs139588200 and rs760575583 are included in TarMart’s mutant protein library to enable early resistance assessment.
Delivery & Safety
Oral bioavailability is essential; no injectables required. Inhibition of AKR1C4 (liver-enriched) must be minimized to avoid hepatic toxicity. Use AKR1C4 in selectivity panels.
Assay Recommendations
- HTS using NADPH depletion (340 nm absorbance) or fluorogenic substrates.
- Selectivity panel: IC50 determination on AKR1C1/1C2/1C3/1C4 under identical conditions (CV <10%).
- Binding validation via SPR or DSF.
- Cellular functional assays: AKR1C1-overexpressing stable lines (MCF-7, K562) with doxorubicin IC50 shift; siRNA knockdown controls.
- Mutant kinetics: Km, Kcat, and inhibitor sensitivity for key mutants.
Related Cross-Sell Targets
- AKR1C2 (View AKR1C2 Products): 98% identity, mandatory counter-screening target.
- AKR1C3 (View AKR1C3 Products): Shared steroid/PG pathway, selectivity control.
- PGR (View PGR Products): Progesterone receptor, downstream endocrine partner.
- ABCB1 (MDR1) (View ABCB1 Products): Multi-drug resistance efflux pump, often co-studied with AKR1C1.